{"id":"W4400327380","doi":"10.1007/s11523-024-01074-9","title":"A Podcast on Platinum Eligibility and Treatment Sequencing in Platinum-Eligible Patients with Locally Advanced or Metastatic Urothelial Carcinoma","year":2024,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Carboplatin; Metastatic Urothelial Carcinoma; Pembrolizumab; Oncology; Internal medicine; Cisplatin; Chemotherapy; Nivolumab; Avelumab; Atezolizumab; Urothelial carcinoma; Immunotherapy; Cancer; Bladder cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006131472,0.0008665732,0.001986244,0.001782717,0.001421683,0.005253294,0.002338035,0.006065624,0.02491097],"category_scores_gemma":[0.02781184,0.0008075209,0.001754744,0.001746751,0.001238274,0.005069708,0.002134126,0.01542676,0.007034482],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.003501114,"about_ca_system_score_gemma":0.004178214,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.005151061,"about_ca_topic_score_gemma":0.01081757,"domain_scores_codex":[0.9974131,0.0008387265,0.0004530333,0.0004675224,0.0005179276,0.0003096988],"domain_scores_gemma":[0.9784167,0.009433243,0.002029564,0.0007200111,0.00488192,0.004518525],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0002552766,0.00007858774,0.0006436679,0.0004418378,0.00003492189,0.00006797927,0.00002844107,0.0001579714,0.00008795276,0.0008059795,0.9042212,0.09317621],"study_design_scores_gemma":[0.0003671633,0.0003163459,0.003263696,0.00300774,0.0001410099,0.0004071685,0.0001536466,0.0004543892,0.0001047834,0.003848753,0.9878743,0.00006093172],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"commentary","genre_gemma":"other","genre_scores_codex":[0.002647096,0.1848581,0.003210942,0.4744958,0.3124678,0.0003146307,0.003398837,0.0006053548,0.01800146],"genre_scores_gemma":[0.02533067,0.280477,0.00807283,0.2374319,0.3978088,0.0006328165,0.005389667,0.0005966998,0.04425963],"genre_candidate":"other","genre_consensus":null,"teacher_disagreement_score":0.02491097,"threshold_uncertainty_score":0.08333558,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02966134817079552,"score_gpt":0.3259758250055169,"score_spread":0.2963144768347213,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}